The JAMA Network Open study scanned about 150,000 posts, and increased appetite was the top complaint. The authors say it can't prove the drug caused it.
Recap by typeshit. Full story at MiNDFOOD.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
The account says researchers still disagree on how to define excess weight and whether obesity counts as a disease.
One user says her period returned after two months on tirzepatide without medroxyprogesterone and asks others to compare.
Loading…